XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXXX
OVERLAYS
Fund
Benchmark
3Y · NAV total return · GBP
Bellevue Funds (Lux) - Bellevue Emerging Markets Healthcare I2 USD: holdings, performance and fees
1Y return+6.6%
3Y return+6.1%
5Y return-29.6%
OCF (ongoing charge)1.54%
Top 10 holdings
| Holding | Weight |
|---|---|
| CELLTRION, INC. | 7.3% |
| BEONE MEDICINES LTD | 7.0% |
| SUN PHARMACEUTICAL INDUSTRIES LIMITED | 6.5% |
| WUXI BIOLOGICS (CAYMAN) INC | 5.9% |
| INNOVENT BIOLOGICS INC | 5.6% |
| SAMSUNG BIOLOGICS CO.,LTD. | 4.4% |
| PHARMAESSENTIA CORPORATION | 3.9% |
| DIVI`S LABORATORIES | 3.5% |
| APOLLO HOSPITALS ENTERPRISES LTD | 3.3% |
| WUXI APPTEC CO LTD | 3.2% |
Top sectors
- Generics/Spec.Pharma36.6%
- Services35.3%
- Biotechnology26.0%
- Other1.6%
- Cash0.4%
Top countries
- China40.4%
- India30.6%
- South Korea15.2%
- Taiwan3.9%
- Thailand3.4%
Holdings, sector and country weightings and performance as reported by FE fundinfo. Weightings are a percentage of the portfolio and may not sum to 100.
AI FORECAST · 12-MONTH
Powered by Claude
FREE PREVIEW
Sign up free to unlock the full AI analysis →
UP—
PREMIUM
PREMIUM
Positives
Risks
600 adviser votes
Upgrade for full forecast →
This is an illustrative, model-generated scenario based on stated assumptions. It is not a prediction, a forecast of actual returns, or investment advice. Outcomes may differ materially. Past performance is not a guide to future returns. Capital is at risk.
PORTFOLIO BREAKDOWN